Effect of Pneumococcal Vaccination: A Comparison of Vaccination Rates in Patients with Bacteremic and Nonbacteremic Pneumococcal Pneumonia

Musher, Daniel M.; Rueda-Jaimes, Adriana M.; Graviss, Edward A.; Rodriguez-Barradas, Maria C.
October 2006
Clinical Infectious Diseases;10/15/2006, Vol. 43 Issue 8, p1004
Academic Journal
Background. Despite the widespread acceptance of the 23-valent pneumococcal capsular polysaccharide vaccine (PPV), its protective effect continues to be disputed. We describe a novel approach to examine the protective effect of this vaccine. Methods. We recorded the vaccination status of every patient for whom a culture yielded Streptococcus pneumoniae during a 4.5-year period, comparing rates of prior PPV administration in patients with (1) bacteremic pneumococcal pneumonia, (2) all-invasive pneumococcal disease, (3) nonbacteremic pneumococcal pneumonia, (4) acute exacerbation of chronic bronchitis (AECB) due to S. pneumoniae, and (5) pneumococcal colonization. The principal comparisons were with patients who had bacteremic pneumonia or any invasive pneumococcal disease and those with nonbacteremic pneumococcal pneumonia. We also compared vaccination rates in patients who had nonbacteremic pneumonia with vaccination rates in patients with AECB or pneumococcal colonization. Results. The rate of prior PPV vaccination was lower among patients with bacteremic pneumococcal pneumonia (39.7%) or any invasive pneumococcal disease (38.0%) than among patients with nonbacteremic pneumonia (57.6%), AECB (60.0%), or pneumococcal colonization (57.8%). PPV conferred a 54% protection rate against bacteremic versus nonbacteremic pneumococcal pneumonia. There was no apparent protection against nonbacteremic pneumonia compared, for example, with colonized persons or with those who had AECB. Conclusions. PPV provides moderate protection against invasive pneumococcal disease but does not protect against nonbacteremic pneumococcal pneumonia. These findings suggest the importance of a continued search for a better pneumococcal vaccine.


Related Articles

  • Recommendations of the Immunization Practices Advisory Committee Pneumococcal Polysaccharide Vaccine.  // JAMA: Journal of the American Medical Association;3/3/89, Vol. 261 Issue 9, p1265 

    Outlines recommendations by the Immunization Practices Advisory Committee (ACIP) on pneumococcal polysaccharide vaccine. Statistics on disease caused by Streptococcus pneumoniae in the United States; Mortality from pneumococcal disease; Formulation of pneumococcal vaccine; Vaccine efficacy;...

  • Capsular Serotype-Specific Attack Rates and Duration of Carriage of Streptococcus pneumoniae in a Population of Children. Sleeman, Karen L.; Griffiths, David; Shackley, Fiona; Diggle, Linda; Gupta, Sunetra; Maiden, Martin C.; Moxon, E. Richard; Crook, Derrick W.; Peto, Timothy E. A. // Journal of Infectious Diseases;9/1/2006, Vol. 194 Issue 5, p682 

    Background. The relative invasiveness rates (attack rates) of Streptococcus pneumoniae of different capsular serotypes in children are not known. Estimates of capsular serotype invasiveness (designated ‘invasive odds ratios’) that are based on cross-sectional prevalence carriage...

  • Changing Characteristics of Invasive Pneumococcal Disease in Metropolitan Atlanta, Georgia, after Introduction of a 7-Valent Pneumococcal Conjugate Vaccine. Albrich, W. C.; Baughman, W.; Schmotzer, B.; Farley, M. M. // Clinical Infectious Diseases;6/15/2007, Vol. 44 Issue 12, p1569 

    Background. The rate of invasive pneumococcal disease (IPD) has decreased among both immunized children and nonimmunized adults since the licensure of a heptavalent pneumococcal conjugate vaccine (PCV7) for use in infants in the United States in 2000. Methods. Temporal trends in IPD incidence,...

  • Overview of pneumococcal serotypes and genotypes causing diseases in patients with chronic obstructive pulmonary disease in a Spanish hospital between 2013 and 2016. Shoji, Hisashi; Vázquez-Sánchez, Daniel A; Gonzalez-Diaz, Aida; Cubero, Meritxell; Tubau, Fe; Santos, Salud; García-Somoza, Dolores; Liñares, Josefina; Yuste, José; Martí, Sara; Ardanuy, Carmen // Infection & Drug Resistance;Sep2018, Vol. 11, p1387 

    Background: Streptococcus pneumoniae is an important pathogen in chronic obstructive pulmonary disease (COPD). We aimed at showing the recent changes in the epidemiology of pneumococcal diseases in patients with COPD, especially after the introduction of the 13-valent pneumococcal conjugate...

  • Nasopharyngeal Carriage of Streptococcus pneumoniae Shortly before Vaccination with a Pneumococcal Conjugate Vaccine Causes Serotype-Specific Hyporesponsiveness in Early Infancy. Dagan, Ron; Givon-Lavi, Noga; Greenberg, David; Fritzell, Bernard; Siegrist, Claire-Anne // Journal of Infectious Diseases;5/15/2010, Vol. 201 Issue 10, p1570 

    Background. The antibody response to pneumococcal conjugate vaccines (PCVs) in infants is variable. Factors responsible for this variability have not been fully elucidated. The objective of this study was to investigate whether pneumococcal carriage around the time of the first dose of 7-valent...

  • Bacteremia in children following introduction of conjugated pneumococcal vaccines. Greenhow, T. L.; Hung, Y. Y.; Herz, A. // Canada Communicable Disease Report;May2017, Vol. 43 Issue 5, p119 

    Background and objectives: In June 2010, Kaiser Permanente Northern California replaced all 7-valent pneumococcal conjugate vaccine (PCV7) vaccines with the 13-valent pneumococcal conjugate vaccine (PCV13). Our objectives were to compare the incidence of bacteremia in children three to 36 months...

  • WHAT'S NEW IN DRUGS.  // RN;Dec79, Vol. 42 Issue 12, p101 

    Presents information on a polyvalent pneumococcal vaccine for the immunization of patients against pneumococci infections. Patients qualified for the vaccine; Infections prevented by the vaccine; Contraindications.

  • THE EFFICACY AND EFFECTIVENESS OF PNEUMOCOCCAL CONJUGATE VACCINES. Klugman, Keith P. // Vaccines: Preventing Disease & Protecting Health;2004, p104 

    Information on the efficacy and effectiveness of vaccines to fight Streptococcus pneumoniae from a chapter of the book "Vaccines: Preventing Diseases & Protecting Health" is presented. The introduction of pneumococcal conjugate vaccine into the routine immunization program of the U.S. is...

  • Pneumococcal vaccination. Burns, Jackie // Primary Health Care;Nov2006, Vol. 16 Issue 9, p18 

    The article offers information on the pneumococcal vaccination in Great Britain. According to published audit figures, the cumulative coverage rate of pneumococcal vaccinations in the 65 and over group is 64.4 percent. A pneumococcal vaccine may be administered at any time and is often easier to...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics